Sodium–glucose cotransporter type 2 (SGLT2) inhibitors are an emerging oral glucose-lowering therapy. In May 2015, the United States Food and Drug Administration issued a warning amid observation of ketoacidosis cases that may have been associated with SGLT2 inhibitor use in people with type 2 diabetes (T2DM). Potential mechanisms include inhibition of insulin secretion through glycosuria, increased glucagon secretion and hypovolaemia.1-3
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.